Department of Surgery and Integrated Clinic-Periodontics Division, School of Dentistry, São Paulo State University (UNESP), Araçatuba, Brazil.
Department of Basic Science, School of Dentistry, São Paulo State University (UNESP), Araçatuba, Brazil.
J Clin Periodontol. 2018 Feb;45(2):241-252. doi: 10.1111/jcpe.12824. Epub 2017 Dec 5.
The purpose of this study in animals was to evaluate the peri-implant bone repair against systemic administration of the antineoplastic agent.
We used 84 male rats (Rattus norvegicus, albinus, Wistar), divided into two groups: cisplatin (CIS) and saline solution (SS). The titanium implants were inserted into the right tibia at day 0 in all animals from both groups. Group SS received SS intraperitoneally at 15 and 17 days postoperatively. Group CIS received 5 and 2.5 mg/kg of CIS intraperitoneally at 15 and 17 days postoperatively, respectively. Euthanasia was performed at 22, 30 and 60 days postoperatively. Twenty-four undecalcified specimens were prepared for histometric analysis of bone/implant contact (BIC). Sixty specimens were selected to bone area (BA) measurement, histological analysis and immunohistochemical analysis of RUNX-2, osteocalcin (OCN) and tartrate-resistant acid phosphatase (TRAP). BIC and BA were considered to be the primary outcome parameters.
Group CIS showed lower BIC (11.87 ± 0.97 mm; 19.19 ± 0.8 mm; 17.69 ± 1.05 mm; p ≤ .05) and BA (3.68 ± 1.29 mm ; 3.05 ± 0.88 mm ; 3.23 ± 0.67 mm ; p ≤ .05), as well as decreased number of RUNX-2 (102.8 ± 27.35 cells/mm ; 100.04 ± 8.61 cells/mm ; 118.82 ± 21.38 cells/mm ; p ≤ .05)- and OCN-positive cells (120 ± 24.5 cells/mm ; 102 ± 27.73 cells/mm ; 100 ± 14.23 cells/mm ; p ≤ .05) at 22, 30 and 60 days, respectively. The animals in group CIS also showed increased number of TRAP-positive cells (86.8 ± 6.37 cells/mm ; 71.5 ± 4.72 cells/mm ; 92.8 ± 9.52 cells/mm ; p ≤ .05) and a persistent and exacerbated inflammatory response in all experimental periods.
Within the limits of this study, it was concluded that the chemotherapeutic CIS negatively affects the bone repair at peri-implant areas, jeopardizing the osseointegration of titanium implants.
本研究旨在评估抗肿瘤药物全身给药对种植体周围骨修复的影响。
我们使用 84 只雄性大鼠（白化挪威鼠，Wistar），分为两组：顺铂（cisplatin，CIS）组和生理盐水（saline solution，SS）组。所有动物在第 0 天于右侧胫骨植入钛种植体。SS 组术后 15 天和 17 天分别给予腹腔内 SS 治疗。CIS 组术后 15 天和 17 天分别给予腹腔内 5 和 2.5mg/kg CIS 治疗。术后 22、30 和 60 天进行安乐死。制备 24 个未经脱钙的标本进行骨/种植体接触（bone/implant contact，BIC）的组织学分析。选择 60 个标本进行骨面积（bone area，BA）测量、组织学分析和 RUNX-2、骨钙素（osteocalcin，OCN）和抗酒石酸酸性磷酸酶（tartrate-resistant acid phosphatase，TRAP）的免疫组织化学分析。BIC 和 BA 被认为是主要的观察指标。
CIS 组的 BIC（11.87±0.97mm；19.19±0.8mm；17.69±1.05mm；p≤0.05）和 BA（3.68±1.29mm；3.05±0.88mm；3.23±0.67mm；p≤0.05）较低，RUNX-2（102.8±27.35 个细胞/mm；100.04±8.61 个细胞/mm；118.82±21.38 个细胞/mm；p≤0.05）和 OCN 阳性细胞（120±24.5 个细胞/mm；102±27.73 个细胞/mm；100±14.23 个细胞/mm；p≤0.05）数量也较少，分别在术后 22、30 和 60 天。CIS 组动物的 TRAP 阳性细胞（86.8±6.37 个细胞/mm；71.5±4.72 个细胞/mm；92.8±9.52 个细胞/mm；p≤0.05）数量也增加，且在所有实验期间持续存在并加剧炎症反应。
在本研究范围内，我们得出结论，化疗药物顺铂对种植体周围区域的骨修复有负面影响，危及钛种植体的骨整合。
